Satellite Symposia

Satellite symposia descriptions will be posted as they are confirmed. Please visit this page regularly for updated information.  

Thursday, April 25

Satellite Symposium - Eli Lilly (17:00 - 18:15)

Collaborate & Connect in the Care of HR+/HER2-mBC: Taking a Multidisciplinary Approach to Optimizing Treatment with CDK4/6 Inhibitors

Dr. Sandy Sehdev, Ottawa Cancer Center, Ottawa, ON
Dr. Scott Edwards, Eastern Health, St. John’s, NB
Massey Nematollahi, William Osler, Brampton, ON

In contrast to treatments like chemotherapy, toxicities associated with CDK4/6 inhibitors can be limited by dose reductions and modifications. Therefore, it is critical to have multiple healthcare providers monitoring patients throughout the treatment process to ensure the early identification of any side effects or treatment complications. Open communication amongst a patient’s multi-disciplinary oncology team ensures all stakeholders can quickly act upon the onset of any adverse events to:

  • Minimize the impact of adverse events
  • Avoid prolonged treatment interruptions
  • Maintain patient confidence in their treatment plan

Learning Objectives:

  1. Identify the role that new evidence and treatment options play in the management of HR+/HER2-mBC;
  2. Implement practical strategies around side effect management, monitoring requirements, and dosing recommendations for CDK4/6 inhibitors; and
  3. Discuss best practices to optimize the impact of multidisciplinary teams in HR+/HER2-mBC.

Satellite Symposium - Novartis (18:30 - 20:00)

Clinical Pursuit: Developing a Game Plan for Treatment Selection and Adverse Event Management in Advanced Breast Cancer

Dr. Scott Edwards, PharmD, MSc, Clinical Oncology Pharmacy Specialist, Cancer Care Program and Clinical Assistant Professor of Oncology (Pharmaceutical Sciences), Memorial University, St. John’s, NL
Dr. Alia Thawer, PharmD, Pharmacist, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON

With the development of new groundbreaking therapies for advanced breast cancer, patients are living longer and better lives. Additionally, as oral therapies begin to play an increasingly significant role in the management of advanced breast cancer, quality of life is becoming a progressively more important factor to consider, both in treatment selection and in ongoing patient monitoring and management.  

In this interactive symposium, participants will divide into two teams and assess their knowledge of advanced breast cancer management. Through this group quiz show-style format, oncology pharmacists will review data and provide tips on ensuring the right therapy is selected for the right patients to maximize therapeutic success and quality of life. Focused discussions will also uncover practical strategies for counselling, monitoring and managing adverse events in patients with advanced endocrine-resistant ER-positive breast cancer treated with oral targeted agents. 

Learning Objectives:

  1. Examine the impact of recent treatment advances on the management of advanced endocrine-resistant ER-positive breast cancer;
  2. Review data on quality of life and the use of oral targeted agents in special populations with advanced breast cancer;
  3. Counsel patients with advanced endocrine-resistant ER-positive breast cancer regarding potential adverse events due to oral targeted agents; and
  4. Monitor and manage adverse events due to CDK4/6 inhibitors or mTOR inhibitors.

Friday, April 26

Satellite Symposium - LEO Pharma (07:00 - 08:30)

How Drug-Drug-Interactions and Adverse Event Profiles should Influence Optimal Choice of Anticoagulant Therapy in Cancer Patients

Thomas R.J. McFarlane, BScPhm, PharmD, RPh, Clinical Lecturer/Pharmacy Teaching Fellow, University of Waterloo, Waterloo, ON
Sandy Sehdev, MD, FRCPC, Medical Oncologist, The Ottawa Hospital Cancer Centre, Ottawa, ON

Venous thromboembolism is a significant source of morbidity and mortality in cancer patients, with a rapidly evolving treatment landscape. Multiple options are available to treat this condition and it is now recognized that patient selection is critical to ensure positive outcomes. 

The goal of this symposium is to help healthcare providers understand how to tailor anticoagulation in the context of the latest clinical trials. 

Key safety issues when selecting therapy to treat cancer-associated thrombosis will be highlighted, with a particular focus on the potentially underappreciated risks arising from drug-drug interactions and adverse events related to common cancer treatment (and supportive) regimens.

Learning Objectives:

  1. Discuss how to mitigate risks associated with anticoagulation treatment in Cancer Associated Thrombosis;
  2. Raise awareness of how the risk of Drug-Drug-Interactions may impact efficacy and safety of anticoagulation; and
  3. Review how Adverse Event profiles of concomitant medications may impact safety of anticoagulation. 

Satellite Symposium - Apobiologix (8:45 - 10:15)

Ethical and Practical Considerations When Incorporating Biosimilars into Oncology Practice

Although there are only a handful of biosimilars in oncology approved by Health Canada to date, there are many more in the pipeline. Considering early adoption and expectations of an increasing number of biosimilars, the Canadian oncology community is anticipating the necessary changes. While the regulatory agency has an established framework for biosimilar approvals and payers have started to shape reimbursement policies, there are additional aspects that providers and institutions will face that require thoughtful consideration. What are the ethical considerations when incorporating biosimilars into oncology practice? How will biosimilars be incorporated efficiently, effectively and seamlessly into practice? This symposium will explore and debate ethical and practical aspects related to the use of biosimilars in oncology with the goal of helping shape a solution through awareness and discussion.

Satellite Symposium - Amgen (10:30 - 12:00)

Anatomy to Administration: Preparing the Oncology Pharmacist for a changing metastatic colorectal cancer treatment landscape

The use of biologics in metastatic colorectal cancer (mCRC) treatment continues to be refined and become more personalized. Therapeutic biosimilars such as bevacizumab, will soon become a treatment option for the management of mCRC. The integration of biosimilars into clinical practice will present unique opportunities and challenges for oncology pharmacists as they navigate first-line treatment options. Join us as we discuss vital topics in mCRC and explore strategies to personalize patient care in the changing treatment landscape.

Learning Objectives:

  1. Describe patient and tumour factors that impact choice of biologic (VEGF inhibitor vs EGFR inhibitor) in patients receiving first-line treatment for mCRC; 
  2. Communicate the totality of evidence supporting the use of biosimilar bevacizumab in mCRC, specifically the rationale for authorization of indications;
  3. Explain the pan-Canadian Oncology Biosimilar Initiative and the role it will play in the practical considerations including implementation of biosimilars into pharmacy practice; and
  4. Support patients with personalized therapy-options as they navigate through the changing mCRC treatment landscape.

Satellite Symposium - Teva (12:15 - 13:45)

Are You and Your Centre Ready for Biosimilars? Lessons Learned From the United Kingdom Experience

Pharmacists play an important role in planning for the introduction therapeutic biosimilars, to make necessary changes to practice and provide education about biosimilars to meet the individualized needs of patients and the broader healthcare system.  This symposium will provide pharmacists with practical guidance on how to logistically prepare for the arrival of biosimilars in oncology and integrate them into clinical practice. Using a practical presentation-based and panel discussion format, topics important to the introduction of biosimilars, such as prescribing, administration, labelling, and education, and how to equip the pharmacy workspace in preparation for the implementation of biosimilars will be discussed.  

Learning Objectives:

  1. Apply key learnings from the UK pharmacy practice experience;
  2. Discuss the safety and efficacy of biologics and biosimilars for the treatment of cancers;
  3. Integrate oncology biosimilars into Canadian pharmacy practice; and
  4. Describe the Pan-Canadian Oncology Biosimilars Initiative.

Satellite Symposium - Pfizer Injectables (14:00 - 15:30)

How to Tailor Anticoagulation in Cancer-Associated Thrombosis: LMWH or DOAC?

Learning Objectives:

  1. Review latest data on use of new oral antiagulants for cancer-associated thrombosis (CAT);
  2. Choose optimal VTE treatment in CAT patients based on latest evidence; and
  3. Understsand the importance of the role of the pharmacists in the management of CAT.

Satellite Symposium - Ipsen (15:45 - 17:15)

Advances in the Management of locally Advanced Renal Cell Carcinoma (aRCC)

Learning Objectives:

  • To facilitate peer to peer exchange and sharing through clinical case discussions in Advanced Renal Cell Carcinoma (aRCC);
  • To present clinical evidence for new therapies in the treatment of aRCC including a new multi-targeted TKI therapy; and
  • To review and discuss optimal patient management in aRCC.

Satellite Symposium - AbbVie (17:30 - 19:00)

CLL: Are We Ready for Another Revolution?

Dr. Versha Banerji MD, FRCPC, Haematologist, Department of Haematology & Oncology , CancerCare Manitoba, Winnipeg, MB 
Lily Spasic, BSc.Pharm, Rph, MSc, Clinical Oncology Pharmacist, Stronach Regional Cancer Centre, Newmarket, ON

This program aims to inform the audience of recent treatment advances in CLL, including data on patient outcomes in regards to safety and efficacy. The symposium will also address how these changes are impacting the healthcare system with mention of potential solutions to ensure optimal outcomes and system sustainability. 

Learning Objectives:

  1. Describe disease management and recent treatment advances in CLL; 
  2. Recognize cost-effective and sustainable therapeutic strategies in the management of CLL patients; and
  3. Assess the safety of current treatments in the management of CLL.

Saturday, April 27

Satellite Symposium - BD (7:00 - 8:30)

Healthcare Workers' Exposure to Antineoplastic (Hazardous) Drugs

Dr. Chun-Yip Hon, PhD, CPHI(C), CRSP, CIH, Associate Professor, School of Occupational and Public Health, Ryerson Univeristy, Toronto, ON

According to CAREX Canada, about 75,000 Canadian healthcare workers, including pharmacists, physicians and other caregivers, are potentially exposed to hazardous drugs1.   This exposure is putting them at risk of both short- and long-term health issues such as headaches, hair loss, nausea, reproductive problems,2 genetic effects and even cancer.3   Occupational exposure is primarily through contact with the drugs (IV bags or the vials) or indirectly through touching a drug-contaminated surface.  Drug contamination has been found on surfaces throughout the hospital medical circuit and is not just isolated to the pharmacy and drug administration units.4   To minimize these risks, healthcare facilities should comply with safe drug handling standards, guidelines and recommendations including regular surface wipe testing or environmental monitoring.  In addition to assessing risk of exposure to hazardous drugs, surface wipe testing can be used to evaluate cleaning efficacy as well as determine the effectiveness of control measures. The National Association of Pharmacy Regulatory Authorities (NAPRA) recommends hazardous drug contamination should be measured at least every 6 months.5 

1. Carex Canada, 2018.
2. Connor TH, Lawson CC, Polovich M, McDiarmid MA. Reproductive health risks associated with occupational exposures to antineoplastic drugs in health care settings: a review of the evidence. J Occup Environ Med. 2014;56(9):901-910.
3. Hansen J, Olsen JH. Cancer morbidity among Danish female pharmacy technicians. Scand J Work Environ Health. 1994;20(1):22-26.
4. Hon CY, Teschke K, Chu W, Demers P, Venners S. Antineoplastic drug contamination of surfaces throughout the hospital medication system in Canadian hospitals. Journal of Occupational and Environmental Hygiene. 2013;10(7):374-83.
5. National Association of Pharmacy Regulatory Authorities. (2016). Model Standards for Pharmacy Compounding of Hazardous Sterile Preparations. Ottawa: NAPRA.

Learning Objectives:

  1. What is surface contamination?;
  2. Review results from the literature;
  3. Occupational exposure limits;
  4. How to test for surface comtamination;
  5. Way to reduce surface contamination; and
  6. Policy considerations (to reduce exposure).

Sunday, April 28

Satellite Symposium - Baxter (7:00 - 8:30)

Understanding and Implementing Dose Banding: Approaches to Manage Drug Wastage Costs When Complying with NAPRA BUD Requirements

Dr. Alicia Wall, Regional Manager of Oncology Pharmacy Services, Eastern Health, Newfoundland
Dr. Darryl Boehm, Director of Pharmacy, Saskatchewan Cancer Agency, Saskatchewan

The incidence of cancer diagnosis in Canada is rising, resulting in an increase in the number of chemotherapy drugs.  The increasing cost of chemotherapy drugs puts a demand on healthcare resources.  The NAPRA compounding 6-hour beyond use date standard for single dose vials is expected to increase drug expenditures.  Cancer Care Ontario recommends dose banding to help with system efficiencies, reduce wait times and minimize drug waste.  This symposium will review the benefits of dose banding, describe the evidence to support dose banding and outline a practical approach and evaluation of implementing dose banding at Eastern Health and Saskatchewan Cancer Agency.                                        

Satellite Symposium - Pfizer Oncology (12:30 - 14:00)

Development of an Institutional Multi-Disciplinary Management Pathway for Patients on CDK 4/6 Inhibitors: Sharing Best Practices

Alia Thawer, Sunnybrook Health Sciences Centre, ON

CDK 4/6 Inhibitors have revolutionized the treatment landscape for locally advanced and metastatic ER+ HER 2- Breast Cancer. Patients on these agents need close monitoring and thus strategies that best utilize the unique skill set of all participating healthcare professionals are required to ensure patients on CDK 4/6 Inhibitors receive both safe and efficient care. This session is designed to describe the experience at a single institution in designing and implementing a care pathway for these patients, but also to share best practices being developed across the country. This is an opportunity to learn from each other and innovate together.

Learning Objectives:

  1. Describe how an effective and efficient care pathway was implemented at a single institution to optimize the care of patients receiving CDK 4/6 inhibitors for HR+/Her2- mBC;
  2. Identify practical strategies for the management of side effects, monitoring requirements, as well as dosing recommendations for CDK4/6 inhibitors; and
  3. Discuss country wide best practices that have leveraged the unique skill set of a multidisciplinary team and assisted in optimizing the care of patients on these unique and valuable treatment advances.